# Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients

Study · id `cardio:ct-nct06381947` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06381947](<https://clinicaltrials.gov/study/NCT06381947>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06381947

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 130 participants.

## Technical summary

Registry record NCT06381947. Randomized; no masking; primary purpose prevention. Start 2024-05-01 (anticipated); primary completion 2025-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 130 participants (planned count; ClinicalTrials.gov record NCT06381947, source copy `cardio:ctgov-nct06381947-2024-04-24`, retrieved 2026-10-31)
- Planned start: 2024-05-01 (anticipated) (ClinicalTrials.gov record NCT06381947, source copy `cardio:ctgov-nct06381947-2024-04-24`, retrieved 2026-10-31)
- Primary completion: 2025-06-30 (anticipated) (ClinicalTrials.gov record NCT06381947, source copy `cardio:ctgov-nct06381947-2024-04-24`, retrieved 2026-10-31)
- Completion: 2025-06-30 (anticipated) (ClinicalTrials.gov record NCT06381947, source copy `cardio:ctgov-nct06381947-2024-04-24`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06381947-2024-04-24`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients
- Acronym: BESAFE
- Condition: Dyslipidemias
- Condition: Statin Adverse Reaction
- Condition: Cardiovascular Diseases
- Condition: Lipid Metabolism Disorders
- Intervention (Drug): Lipid-lowering therapy combination with PCSK9 inhibitors, bempedoic acid and ezetimibe
- Intervention (Drug): Lipid-lowering therapy combination with PCSK9 inhibitors and ezetimibe
- Lead sponsor: University of Salerno
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)

## Provenance

Content hash: b29d4c70f0fe636b7020e4136e721f12059e6573f8950cba1383840f3c4eeb02
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
